Key players: Individuals include Tom Sundlof (ex-FDA attorney with 20+ years advising on medical devices, combination products, enforcement, and policy) and host Eric Tower; organizations are Blank Rome LLP (Sundlof's new firm), FDA (especially CDRH issuing FY2026 guidance lists on devices, plus January 6, 2026 updates on General Wellness: Policy for Low-Risk Devices and Clinical Decision Support Software), and prior role at U.S. House Office of General Counsel; no specific legislation, but context ties to upcoming user fee agreements (UFAs) reauthorization by September 2027.[1][2][3][7][9][10][13]
Basic context and timeline: Sundlof's FDA tenure (until ~Jan 2024) involved leading legal strategies on rulemakings, guidances, premarket reviews, and AI/digital health; he transitioned to Blank Rome recently amid FDA's 2026 priorities like CDRH A/B-list guidances, reissued Device Software Functions policy, expanded wellness exemptions for low-risk wearables/noninvasive trackers, CDS refinements (e.g., broader "medical information" definition, AI transparency to curb bias), and UFA negotiations starting 2026—driven by leadership changes, political pressures, and innovation in AI devices/remote monitoring.[1][2][3][5][7][9][10][11][13][15] Podcast leverages his expertise post-hire, post-January guidances.
Why newsworthy now: Released March 25, 2026—just after FDA's January 6 CES-touted deregulatory guidances loosening oversight on digital health/wellness tools (e.g., enforcement discretion for low-risk CDS/AI, non-regulation of certain wearables)—the episode spotlights timely shifts amid UFA talks, agency turnover, and booming AI/medical device innovation, aiding firms navigating 2026 compliance/market access.[3][10][13][15]